Table 10 Incidence of hematological adverse effects with different neoadjuvant treatment regimens, regardless of BRCA status
|  | Cisplatin alone | Carboplatin + anthracycline + taxane | Carboplatin + taxane | Carboplatin + Gemcitabine + PARPi | Carboplatin + NACT + PARPi | Carboplatin + NACT + anti-VEGF antibody | PARPi | Carboplatin + Eribulin |
|---|---|---|---|---|---|---|---|---|
n | 196 | 106 | 239 | 93 | 398 | 1246 | 52 | 30 |
Adverse effect | ||||||||
 Neutropenia | 3.6% | 50.9% | 10.5% | 45.2% | 59.0% | 76.6% | 5.8% | 60.0% |
 Anemia | 1.0% | 20.8% | 4.2% | 8.6% | 25.1% | 5.0% | 15.4% | 23.3% |
 Febrile neutropenia | 0.5% | 18.9% | 3.3% |  | 1.5% | 12.4% |  |  |
 Thrombocytopenia |  | 12.3% | 5.4% | 6.5% | 13.1% | 5.0% | 1.9% | 20.0% |
 Leukopenia |  | 12.3% | 0.8% |  | 4.5% |  |  |  |